Net Cash Provided by (Used in) Financing Activities of ImmunityBio, Inc. from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ImmunityBio, Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • ImmunityBio, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $982,000, a 110% decline year-over-year.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $400,241,000, a 42% increase from 2024.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $281,630,000, a 50% decline from 2023.
  • ImmunityBio, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $558,341,000, a 139% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

ImmunityBio, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $400,241,000 +$118,611,000 +42% 01 Jan 2025 31 Dec 2025 10-K 23 Feb 2026 2025 FY
2024 $281,630,000 -$276,711,000 -50% 01 Jan 2024 31 Dec 2024 10-K 23 Feb 2026 2025 FY
2023 $558,341,000 +$324,728,000 +139% 01 Jan 2023 31 Dec 2023 10-K 23 Feb 2026 2025 FY
2022 $233,613,000 -$271,830,000 -54% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $505,443,000 +$354,768,000 +235% 01 Jan 2021 31 Dec 2021 10-K 19 Mar 2024 2023 FY
2020 $150,675,000 +$36,396,000 +32% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $114,279,000 +$115,050,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $771,000 +$34,212,000 +98% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2021 2020 FY
2017 $34,983,000 -$19,423,000 -125% 01 Jan 2017 31 Dec 2017 10-K 25 Mar 2020 2019 FY
2016 $15,560,000 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY

ImmunityBio, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $982,000 -$11,207,000 -110% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $10,225,000 -$66,663,000 -87% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $76,888,000 +$77,186,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $298,000 -$38,795,000 -101% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $38,497,000 +$38,620,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $123,000 -$39,318,000 -100% 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q1 2019 $39,195,000 +$39,280,000 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q1 2018 $85,000 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.